More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, the majority of which are asymptomatic.

In 2020 there were are an estimated 374 million new infections in people 15–49 years with 1 of 4 curable STIs: chlamydia, gonorrhoea, syphilis and trichomoniasis.

An estimated 8 million adults between 15 and 49 years old were infected with syphilis in 2022.

More than 500 million people aged 15–49 years are estimated to have a genital infection with herpes simplex virus (HSV or herpes) (1).

Human papillomavirus (HPV) infection is associated with over 311 000 cervical cancer deaths each year (2).

1.1 million pregnant women were estimated to be infected with syphilis in 2022, resulting in over 390 000 adverse birth outcomes.

STIs have a direct impact on sexual and reproductive health through stigmatization, infertility, cancers and pregnancy complications and can increase the risk of HIV.

Drug resistance is a major threat to reducing the burden of STIs worldwide